In addition to enhancing insulin secretion, GLP-1 agonists suppress glucagon release from pancreatic alpha cells in a glucose-dependent manner
Following a thorough analysis of our previous Phase IIb data and trial design, we are confident that with the preferred modified release formulation and optimized future trial design, we can advance a competitive oral GLP-1 molecule into registration-enabling studies to meet the ongoing medical needs of people living with obesity. The ongoing open-label, randomized study is assessing the pharmacokinetics and safety of immediate- and modified-release formulations of danuglipron administered orally in healthy adults aged 18 years or older
However, it is important to remember that most tick bites will not cause Lyme disease
When Does Type I Collagen Replace Type III During Tendon Healing
Risk Factors That Make Silent Symptoms More Likely Risk factors can increase your chances of developing silent heart disease
Few investigations incorporated clinically relevant comparators, standardized rehabilitation conditions, or endpoints directly translatable to postoperative recovery
